TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10569170

Group type: EXPERIMENTAL
Intervention: Phacoemulsification and intraocular lens (IOL) implantation (AcrySof MA30BA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no striae)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phacoemulsification and intraocular lens (IOL) implantation
Number of subjects: 100
Study: 8740787

Group type: EXPERIMENTAL
Intervention: CMFp (Cyclophosphamide, Methotrexate, 5-Fluorouracil + low-dose prednisone)
Number of subjects: 491

Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: CMFp
Number of subjects: 491

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 491
Study: 1833897

Group type: EXPERIMENTAL
Intervention: Enoximone (2 x bolus 0.5 mg/kg, infusion 5.0 mcg/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dopamine (3-4.0 mcg/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20
Study: 6884167

Group type: EXPERIMENTAL
Intervention: lactulose (40 g)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: metoclopramide (20 mg tds)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: magnesium sulfate (0.1 g/kg body weight)
Number of subjects: 14

Group type: COMPARATOR
Intervention: control conditions
Number of subjects: 14
Study: 30767052

Group type: EXPERIMENTAL
Intervention: Novel mathematical framework including gene conversion in gene tree/species tree reconciliation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized algorithm for reconciliation
Number of subjects: 0
Study: 27461523

Group type: EXPERIMENTAL
Intervention: Heat-stabilized rice bran (30 g/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cooked navy bean powder (35 g/day)
Number of subjects: 29
Study: 26674998

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Kangaroo Father Care (KFC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: KMC and KFC (comparison between parents)
Number of subjects: 26
Study: 25149657

Group type: EXPERIMENTAL
Intervention: Flexion group (knee in 90° flexion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Extension group (knee in full extension)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (same postoperative rehabilitation exercises)
Number of subjects: 80
Study: 22571836

Group type: EXPERIMENTAL
Intervention: Intervention group with social reinforcement
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intervention group without social reinforcement
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study: 19852292

Group type: EXPERIMENTAL
Intervention: Qingyi Decoction (QYD)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 125
Study: 17242078

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.01 mg/kg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 15065643

Group type: EXPERIMENTAL
Intervention: Diet + Sibutramine 1 x 10 mg/d (n=22)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Diet + Orlistat 3 x 120 mg/d (n=25)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination of Diet + Sibutramine + Orlistat (n=20)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Diet (n=19)
Number of subjects: 86
Study: 11642485

Group type: EXPERIMENTAL
Intervention: Division of the pedicle at 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Division of the pedicle at 4 weeks
Number of subjects: 60
Study: 9876861

Group type: EXPERIMENTAL
Intervention: Single session treatment (SS)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Treatment-as-needed intervention (TAN)
Number of subjects: 111
Study: 7994783

Group type: EXPERIMENTAL
Intervention: Epirubicin (40 mg/40 ml saline) given within 24 h of TUR and once during the 1st week, weekly for 4 weeks and then monthly for 11 months
Number of subjects: 135
Study: 2689017

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream (Dermovate) with occlusion using Comfeel Coloplast dressing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream (Dermovate) without occlusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 10
Study: 791319

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol and Pindolol
Number of subjects: 0
Study: 29348183

Group type: EXPERIMENTAL
Intervention: Breathing 60% oxygen during constant-load cycling
Number of subjects: 14

Group type: COMPARATOR
Intervention: Room air during constant-load cycling
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Incremental cycling tests
Number of subjects: 14
Study: 27912875

Group type: EXPERIMENTAL
Intervention: Chamomile (1500mg, 500mg capsule 3 times daily)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Chamomile
Number of subjects: 179
Study: 24462735

Group type: COMPARATOR
Intervention: TDF + placebo (300 mg TDF)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: TDF + emtricitabine (300 mg TDF + 200 mg emtricitabine)
Number of subjects: 126
Study: 22196945

Group type: EXPERIMENTAL
Intervention: Extended nevirapine prophylaxis
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Extended nevirapine
Number of subjects: 1527
Study: 21122701

Group type: EXPERIMENTAL
Intervention: 25 g/d of an insoluble fraction of partially hydrolyzed soy protein (SP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 25 g/d total milk proteins (TMP)
Number of subjects: 0
Study: 18294814

Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Untreated heroin addicts
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study: 16796928

Group type: EXPERIMENTAL
Intervention: Pulmonary artery perfusion with hypothermic washed red blood cell solution during CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 14636805

Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 1704

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1704
Study: 11126231

Group type: EXPERIMENTAL
Intervention: Modified cognitive-behavioural treatment (M-CBT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard cognitive-behavioural therapy (S-CBT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both M-CBT and S-CBT
Number of subjects: 63
Study: 8816537

Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Selective stent placement based on angiographic criteria
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pre- and post-PTA angiograms
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Percentage stenosis and pressure gradient correlation
Number of subjects: 79
Study: 2062772

Group type: EXPERIMENTAL
Intervention: urapidil (30 mg twice daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 6134136

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 6
Study: 30664490

Group type: EXPERIMENTAL
Intervention: Web-based sexual health influencers (SHIs)
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Non-influencers
Number of subjects: 1031
Study: 29522549

Group type: EXPERIMENTAL
Intervention: Secure subliminal priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral subliminal priming
Number of subjects: 0
Study: 26658817

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 52
Study: 25248497

Group type: EXPERIMENTAL
Intervention: Usual care plus WWWT (What Were We Thinking) intervention
Number of subjects: 368

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 368
Study: 22360337

Group type: EXPERIMENTAL
Intervention: Nanosome vitamin C iontophoresis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Glycolic acid 70% peel
Number of subjects: 14
Study: 20359693

Group type: EXPERIMENTAL
Intervention: Alcohol Behavioral Individual Treatment (ABIT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Alcohol Behavioral Couples Treatment (ABCT)
Number of subjects: 102
Study: 17957149

Group type: EXPERIMENTAL
Intervention: Subcutaneous pramlintide injection (5 microg/unit of insulin)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Subcutaneous pramlintide infusion (5 microg/unit of insulin over 120 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Insulin-only administration
Number of subjects: 8
Study: 15750043

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing at 7 beats/minute faster than the mean nocturnal heart rate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing at 15 beats/minute faster than the mean nocturnal heart rate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonpacing
Number of subjects: 20
Study: 12019280

Group type: EXPERIMENTAL
Intervention: Hemodynamic (HD) measurements and a predefined algorithm
Number of subjects: 104

Group type: COMPARATOR
Intervention: Specialist care (SC)
Number of subjects: 104
Study: 10535231

Group type: EXPERIMENTAL
Intervention: PATHS (Promoting Alternative THinking Strategies) curriculum and teacher consultation delivered by Grade 1 teachers, 57 lessons focused on self‐control, emotional awareness, peer relations, and problem solving.
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: PATHS (Promoting Alternative THinking Strategies) curriculum and teacher consultation delivered by Grade 1 teachers.
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Quality of implementation of the PATHS curriculum.
Number of subjects: 378

Group type: COMPARATOR
Intervention: Comparison classrooms (control group).
Number of subjects: 378
Study: 7852517

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50 mg
Number of subjects: 6
Study: 1971034

Group type: EXPERIMENTAL
Intervention: Alteplase (100 mg intravenous plus heparin)
Number of subjects: 5013

Group type: COMPARATOR
Intervention: Placebo plus heparin
Number of subjects: 5013
Study: 399767

Group type: EXPERIMENTAL
Intervention: Modified activities of daily living (ADL) index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospital ADL scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospital scores vs. patients' own estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scores obtained in hospital vs. at home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inter-observer variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term within-patient variability
Number of subjects: 0
Study: 31997417

Group type: EXPERIMENTAL
Intervention: Lack of health insurance
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Poor self-rated general health
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Average self-rated general health
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Monotony of diet
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Absence of dentures
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Insufficient dentures
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Presence of dentures
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 905
Study: 30321764

Group type: EXPERIMENTAL
Intervention: Cyclin D1 overexpression in carcinomas and non-tumour epithelia
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cyclin D1 overexpression in different epithelial layers
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nuclear expressions of cyclin D1 and Ki-67 in the basal layer of distant epithelium
Number of subjects: 54
Study: 29171818

Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (675 mg at baseline, 225 mg at weeks 4 and 8)
Number of subjects: 1130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1130
Study: 25604727

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum R0071
Number of subjects: 581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study: 23433257

Group type: EXPERIMENTAL
Intervention: Chloramphenicol suspension (1 drop)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Chloramphenicol gel (1 application)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Netilmicin suspension (1 drop)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Tobramycin suspension (1 drop)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Chloramphenicol suspension (repeated instillations every 10 min for a total of 4 drops)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Chloramphenicol gel (repeated instillations every 10 min for a total of 4 drops)
Number of subjects: 122
Study: 21297503

Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 19257

Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 19257
Study: 19330661

Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) programme with 10 patient-centred tutorials led by final year tutors over a 5-week ward placement.
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (CG) did not participate in the PAL programme.
Number of subjects: 168
Study: 16730318

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention, weekly sessions over 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention
Number of subjects: 32
Study: 15643634

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11330851

Group type: EXPERIMENTAL
Intervention: classroom instruction enhanced by five homework assignments
Number of subjects: 351
Study: 8986959

Group type: EXPERIMENTAL
Intervention: Planned developmental instruction strategies
Number of subjects: 0
Study: 8280339

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control Phase
Number of subjects: 100
Study: 3611457

Group type: EXPERIMENTAL
Intervention: Standardized measures of stress
Number of subjects: 0
Study: 30185575

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (ICBT) with therapist support
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Unguided internet-based cognitive behaviour therapy (ICBT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Face-to-face cognitive behaviour therapy (f2f CBT)
Number of subjects: 120
Study: 26961111

Group type: EXPERIMENTAL
Intervention: Total risk management (LDL‐C <80 mg/dL, systolic BP <130 mmHg, and HbA1c <6.5%)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Number of risk factors achieving target levels
Number of subjects: 73
Study: 24976447

Group type: EXPERIMENTAL
Intervention: Starting dose of 7.5 mg MTX per week (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Starting dose of 15 mg MTX per week (group 2)
Number of subjects: 100
Study: 21892594

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavior therapy (CBT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Trauma-focused cognitive therapy (CT)
Number of subjects: 33
Study: 21110842

Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavioral therapy (CBT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (patients carrying at least one val-allele)
Number of subjects: 69
Study: 18266402

Group type: EXPERIMENTAL
Intervention: Once-daily inhaled SFC 50 microg/100 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-daily inhaled FP 100 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16983913

Group type: EXPERIMENTAL
Intervention: Zhiling Capsule (ZC) - whole recipe, administered orally for 2 weeks
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Disassembled recipe 1 (Western medicines) of ZC, administered orally for 2 weeks
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Disassembled recipe 2 (Chinese medicines) of ZC, administered orally for 2 weeks
Number of subjects: 250

Group type: COMPARATOR
Intervention: Pingxiao Capsule (Control), administered orally for 2 weeks
Number of subjects: 250
Study: 14534336

Group type: EXPERIMENTAL
Intervention: Gentamicin (0.3 percent, or 3 mg per milliliter) administered topically, three times daily for 14 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo administered topically, three times daily for 14 days
Number of subjects: 19
Study: 11264156

Group type: EXPERIMENTAL
Intervention: GM-CSF priming (250 microg/m(2) twice daily for 5 days before treatment)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Topotecan without GM-CSF priming
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: GM-CSF priming
Number of subjects: 53
Study: 9247942

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg midazolam
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg midazolam
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg midazolam
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 8005970

Group type: EXPERIMENTAL
Intervention: Steroid and cyclophosphamide every other month (Gr-I)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Steroid alone (Gr-II)
Number of subjects: 71
Study: 3551327

Group type: EXPERIMENTAL
Intervention: Combined treatment (preoperative Co‐60 teletherapy + radical surgery)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 234
Study: 29093280

Group type: EXPERIMENTAL
Intervention: Weekly DPP‐4 inhibitor, trelagliptin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Daily DPP‐4 inhibitors
Number of subjects: 49
Study: 28802598

Group type: COMPARATOR
Intervention: Sufentanil (0.04μg/kg/h)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.04μg/kg/h) plus dexmedetomidine (0.06μg/kg/h)
Number of subjects: 152
Study: 25573656

Group type: EXPERIMENTAL
Intervention: Mid-septal RV lead positioning
Number of subjects: 227

Group type: COMPARATOR
Intervention: Apical RV lead positioning
Number of subjects: 227
Study: 23817470

Group type: EXPERIMENTAL
Intervention: 1.6 g DHA/day from a microalgae source with 2.4 g/day carrier oil for 16 weeks
Number of subjects: 328

Group type: COMPARATOR
Intervention: 4.0 g/day olive oil for 16 weeks (control)
Number of subjects: 328
Study: 20543754

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking cadence of 100 steps per minute
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Height-related variables in walking cadence
Number of subjects: 75
Study: 18323500

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin (C+A)
Number of subjects: 0
Study: 16581062

Group type: EXPERIMENTAL
Intervention: Cyclooxygenase‐2 inhibitor parecoxib (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study: 12974197

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) 5 mg/kg per day for 8 weeks, then 4 mg/kg per day for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cetirizine 10 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) 5 mg/kg per day for 8 weeks, then 4 mg/kg per day for 8 weeks (after initial treatment with antihistamines)
Number of subjects: 40
Study: 11074106

Group type: EXPERIMENTAL
Intervention: Patients with a history of violent suicidal behaviour
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patients without a history of violent suicidal behaviour
Number of subjects: 40
Study: 8626361

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 3500
Study: 29945673

Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 0
Study: 26827981

Group type: EXPERIMENTAL
Intervention: Minimal presurgical orthodontics
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional presurgical orthodontics
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 26275718

Group type: EXPERIMENTAL
Intervention: Person-Centred Counselling (8 weekly sessions lasting up to 1 hour)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-Intensity Cognitive Behavioural Therapy (up to 8 weeks of self-help resources with guided telephone support lasting 20-30 minutes each)
Number of subjects: 36
Study: 24130680

Group type: EXPERIMENTAL
Intervention: CPT+AN (suggestions for analgesia)
Number of subjects: 44

Group type: COMPARATOR
Intervention: CPT (without suggestions)
Number of subjects: 44
Study: 21167166

Group type: EXPERIMENTAL
Intervention: High endogenous testosterone levels
Number of subjects: 154

Group type: COMPARATOR
Intervention: Low endogenous testosterone levels
Number of subjects: 154
Study: 18550339

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: COMPARATOR
Intervention: Galantamine vs Placebo
Number of subjects: 43
Study: 15797582

Group type: EXPERIMENTAL
Intervention: Uphill cycling at 60 rpm
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Uphill cycling at 80 rpm
Number of subjects: 7

Group type: COMPARATOR
Intervention: Level ground cycling at 80 rpm
Number of subjects: 7

Group type: COMPARATOR
Intervention: Level ground cycling at 100 rpm
Number of subjects: 7
Study: 11944613

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sargramostim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Molgramostim
Number of subjects: 0
Study: 10738357

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 8526167

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (0.14 mg in each nostril twice a day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ebastine tablets (10 mg as a single night dose)
Number of subjects: 63